GoodRx (NASDAQ:GDRX) Shares Down 7.5% - Here's Why

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) fell 7.5% on Friday . The stock traded as low as $4.18 and last traded at $4.22. 1,135,327 shares were traded during mid-day trading, a decline of 20% from the average session volume of 1,422,404 shares. The stock had previously closed at $4.56.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GDRX. Citigroup reduced their target price on GoodRx from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Wednesday. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. UBS Group dropped their target price on shares of GoodRx from $9.00 to $8.50 and set a "neutral" rating for the company in a research report on Friday, August 9th. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Monday, November 11th. Finally, Raymond James upgraded shares of GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 price objective for the company in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $8.86.

GoodRx Trading Down 9.0 %

The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -138.33, a PEG ratio of 3.22 and a beta of 1.39. The business has a fifty day simple moving average of $6.55 and a 200-day simple moving average of $7.42.

Insider Buying and Selling

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GDRX. Beacon Capital Management LLC bought a new stake in GoodRx in the first quarter valued at $28,000. nVerses Capital LLC bought a new stake in GoodRx in the 3rd quarter valued at about $33,000. Plato Investment Management Ltd acquired a new position in GoodRx during the 2nd quarter worth approximately $43,000. EP Wealth Advisors LLC acquired a new stake in GoodRx in the third quarter valued at approximately $73,000. Finally, Dark Forest Capital Management LP bought a new stake in shares of GoodRx during the second quarter valued at approximately $86,000. Institutional investors and hedge funds own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.